Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KCNMA1 | Q12791 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463572 | 0.89 | HTT (0.70) | HTTLMNANPC1GAAALDH1A1 | |
| SCHEMBL7678596 | 0.88 | LMNA (0.88) | HTTLMNANPC1TP53GAA | |
| SCHEMBL31098214 | 0.87 | HTT (0.73) | HTTLMNANPC1TP53GAA | |
| SCHEMBL845142 | 0.86 | LMNA (1.00) | HTTLMNANPC1TP53GAA | |
| SCHEMBL15333340 | 0.85 | KDM4E (0.78) | HTTLMNANPC1TP53GAA | |
| SCHEMBL28842312 | 0.85 | LMNA (0.96) | HTTLMNANPC1TP53GAA | |
| SCHEMBL28842439 | 0.85 | LMNA (0.96) | HTTLMNANPC1TP53GAA | |
| SCHEMBL2699444 | 0.84 | HTT (0.69) | HTTLMNANPC1TP53GAA | |
| SCHEMBL15541786 | 0.84 | HTT (0.64) | HTTLMNANPC1TP53GAA | |
| SCHEMBL27516656 | 0.84 | LMNA (0.73) | HTTLMNANPC1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012058378-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES L.C. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | ROMARK LABORATORIES, L.C. | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108592-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES | PYGL, GYS2, GLS2 | HTT 3269/4885LMNA 3131/4885NPC1 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.